Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Publishes Phase I Data on ATTR Drugs


Alnylam Pharmaceuticals and collaborators this week published data from phase I trials of the siRNA-based transthyretin amyloidosis drugs ALN-TTR01 and ALN-TTR02 in the New England Journal of Medicine.

The data, which had previously been released by the company (GSN 12/01/2011 & 7/19/2012), show that RNAi-based drugs can achieve rapid, dose-dependent, durable, and specific knockdown of the mutant protein that causes the disease, Alnylam said.

The paper can be found here.

"The phase I studies of ALN-TTR01 and ALN-TTR02 demonstrate key human proof of concept for RNAi therapeutics targeting TTR but also for liver-expressed target genes in general," Alnylam CMO Akshay Vaishnaw said in a statement.

"This new paper describes our clinical trial experience with ALN-TTR01 and ALN-TTR02, which utilize first- and second-generation lipid nanoparticle formulations, respectively," Alnylam Vice President of Clinical Research Jared Gollob added. "We believe the findings published today … suggest that the robust, sustained knockdown of TTR levels observed in our clinical trials with ALN-TTR02 may ameliorate the course of disease in patients with ATTR."

Alnylam has stopped development of ALN-TTR01 in order to focus on ALN-TTR02, which is poised to enter phase III testing before the end of this year. The company is also working on a subcutaneously delivered version of the drug, called ALN-TTRsc, that is slated to enter phase II by the end of 2013.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.